

TRODELVY®

sacituzumab govitecan (Sah see TOO zoo mab GOH vih TEE kan)

Consumer Medicine Information

This leaflet provides important information about using TRODELVY. **You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using TRODELVY.**

Where to find information in this leaflet:

1. Why am I being given TRODELVY?
2. What should I know before I receive TRODELVY?
3. What if I am taking other medicines?
4. How am I given TRODELVY?
5. What should I know while receiving TRODELVY?
6. Are there any side effects?
7. Product details

1. Why am I being given TRODELVY?

TRODELVY contains the active ingredient sacituzumab govitecan.

TRODELVY belongs to a group of medicines known as anti neoplastic (anti-cancer) agents. There are different classes of anti cancer agents.

TRODELVY is designed to work differently to traditional anti-cancer agents (e.g., chemotherapy).

TRODELVY is made up of three components:

- a monoclonal antibody that recognises and attaches to certain cancer cells, and

- a substance intended to kill cancer cells, and
- a linker that links the antibody to the substance.

TRODELVY is designed to target and deliver the anti cancer substance directly to certain cancer cells to stop the growth and spread of the cancer.

TRODELVY is used to treat adults with a type of breast cancer that:

- is oestrogen and progesterone hormone receptor (HR) negative, and human epidermal growth factor receptor 2 (HER2) negative (also called triple negative breast cancer), and
- has spread to other parts of the body or cannot be removed by surgery, and
- has previously been treated with at least two therapies for breast cancer.